Medical Information Notice
This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or qualified healthcare provider. Read full disclaimer
Rotigotine
Quick Facts
- Generic Name
- Rotigotine
- Brand Names
- Neupro
- Drug Class
- Dopamine agonist
- FDA Approved
- 2007
How It Works
Rotigotine is a non-ergot dopamine agonist that stimulates D1, D2, D3, and D5 dopamine receptors, delivered via a once-daily transdermal patch system. The patch provides continuous drug delivery over 24 hours, maintaining stable plasma concentrations and avoiding the peaks and troughs associated with oral medications. This continuous delivery mode more closely mimics the physiological tonic dopamine stimulation that is lost in Parkinson's disease.
What to Expect as a Patient
Rotigotine is unique among PD medications because it is delivered through a skin patch applied once daily. You will need to apply a new patch to a different area of clean, dry, hairless skin each day — good sites include the abdomen, thigh, hip, or upper arm. Rotate sites to prevent skin irritation. Some redness and itching at the application site is normal. You may shower or bathe with the patch on, but avoid applying heat (heating pads, saunas) near the patch as this increases drug absorption. Remove the patch before any MRI scan — this is critical for safety. Expect gradual improvement in symptoms over 2-4 weeks as the dose is titrated upward. Watch for the same class-wide side effects as other dopamine agonists: impulse control problems, sudden sleepiness, and hallucinations.
Typical Dosing
Start 2mg/24hr patch once daily; increase by 2mg/24hr weekly. Early PD max 6mg/24hr; advanced PD max 8mg/24hr. Apply to a different clean, dry, hairless skin site each day (abdomen, thigh, hip, flank, shoulder, upper arm). Rotate sites to minimize skin reactions.
Dosing is individualized by the prescribing physician. The information above is for general reference only.
Common Side Effects
- Application site reactions (redness, itching, irritation)
- Nausea
- Dizziness
- Drowsiness
- Headache
Serious Side Effects
Seek medical attention immediately if you experience any of the following:
- Impulse control disorders
- Sleep attacks
- Hallucinations
- Orthostatic hypotension
- Melanoma risk (theoretical, class-wide)
Contraindications
- Known hypersensitivity to rotigotine or patch components
- Must remove patch before MRI — the aluminum layer can cause skin burns during magnetic resonance imaging
Food Interactions
Transdermal delivery bypasses GI absorption entirely, so food interactions are not a concern. Must remove patch before any MRI scan due to aluminum backing. Rotate application sites daily to reduce skin reactions.
Drug Interactions
The following interactions have been documented with Rotigotine. Always inform your healthcare provider about all medications you are taking.
Rotigotine patch provides continuous dopaminergic stimulation as adjunct to levodopa, potentially smoothing motor fluctuations.
Clinical effects: Increased dopaminergic effects: nausea, dyskinesia, orthostatic hypotension, hallucinations.
Management: Standard combination in advanced PD. Continuous transdermal delivery may reduce pulsatile stimulation-related complications. May allow levodopa dose reduction.
Two dopamine agonists should not be combined as the risk of adverse effects increases substantially without additional benefit.
Clinical effects: Excessive dopaminergic stimulation: severe nausea, hallucinations, impulse control disorders, orthostatic hypotension, sleep attacks.
Management: Do not use concurrently. Switch between agents with appropriate cross-titration and washout.
How Rotigotine Compares to Alternatives
Rotigotine is one of four dopamine agonists available for PD (with pramipexole, ropinirole, and apomorphine). Its unique transdermal delivery offers several advantages: continuous 24-hour drug delivery (vs. peaks and troughs with oral formulations), bypassing GI absorption (useful for swallowing difficulty or perioperative situations), and simple once-daily application. Disadvantages include skin reactions (up to 40% of patients), inability to rapidly adjust doses, and the need to remove patches before MRI. Compared to pramipexole and ropinirole, rotigotine has a broader receptor profile (D1-D5 vs. D2/D3), though whether this translates to clinical advantages is debated.
When Is Rotigotine Used by Disease Stage?
Early PD (Stages 1-2): Can be used as initial monotherapy. Particularly appropriate for patients who prefer patch delivery, have mild swallowing difficulty, or want once-daily simplicity. Mid-stage PD (Stage 2.5-3): Added to levodopa to reduce off-time. The continuous delivery may complement levodopa's pulsatile oral dosing. Advanced PD (Stages 4-5): Particularly valuable when swallowing difficulty (dysphagia) makes oral medication unreliable. Can be maintained during surgery or NPO periods when oral medications cannot be given.
Additional Notes
The only transdermal PD treatment available. Uniquely useful for patients who cannot swallow oral medications (during NPO periods, surgery, severe dysphagia) or who have erratic GI absorption. Provides more continuous dopaminergic stimulation than oral agonists, which may reduce motor fluctuations. Also FDA-approved for restless legs syndrome. Broader receptor profile (D1-D5) than pramipexole or ropinirole (D2/D3 only).
Clinical Perspective
Rotigotine fills a unique niche as the only transdermal PD treatment. Its greatest practical value is in situations where oral medication is impractical: perioperative care, severe dysphagia, and patients who simply prefer a daily patch over multiple pills. The continuous delivery model aligns with the emerging understanding that pulsatile dopaminergic stimulation contributes to motor complications. In practice, skin reactions remain the main barrier to wider use — up to 40% of patients report some degree of application site irritation, though fewer than 10% discontinue for this reason.
This perspective is based on published clinical evidence and guidelines. Individual treatment decisions should always be made with your neurologist.
Sources
- [1]LeWitt PA, Lyons KE, Pahwa R, et al. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER study. Neurology. 2007;68(16):1262-1267
- [2]Giladi N, Boroojerdi B, Korczyn AD, et al. Rotigotine transdermal patch in early Parkinson disease: a randomized, double-blind, controlled study vs. placebo and ropinirole. Mov Disord. 2007;22(16):2398-2404
- [3]Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011;26(1):90-99
- [4]Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease. Arch Neurol. 2010;67(5):589-595
- [5]Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670-1683
Share this article